Coronavirus vaccine compositions and methods of use
AssigneeThomas Jefferson University
InventorsDouglas Craig Hooper, Bernhardt Dietzschold
Life of this patent
Estimating the term…
Abstract
Provided is a method of enhancing an antigen-induced long-lasting immune response in a host comprising administering to a host an effective amount of: (a) a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the glycoprotein amino acid 194 is serine and the glycoprotein amino acid 333 is glutamic acid, wherein said recombinant rabies virus does not express a foreign protein antigen; and (b) a Coronavirus antigen that is not expressed by the rabies virus. Also provided are related compositions, kits and vaccines.
Claims28
A method of inducing an immune response against a coronavirus in a subject comprising administering to the subject an effective amount of:
- (a) a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the glycoprotein amino acid 194 is serine and the glycoprotein amino acid 333 is glutamic acid, wherein said recombinant rabies virus does not express a foreign protein antigen;
- and
- (b) a Coronavirus antigen, or a nucleic acid molecule encoding a Coronavirus antigen, wherein the Coronavirus antigen is not expressed by the rabies virus.
A composition comprising:
- (a) a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the glycoprotein amino acid 194 is serine and the glycoprotein amino acid 333 is glutamic acid, wherein said recombinant rabies virus does not express a foreign protein antigen;
- and
- (b) a Coronavirus antigen, or a nucleic acid molecule encoding a Coronavirus antigen, wherein the Coronavirus antigen is not expressed by the rabies virus.
A kit for immunization of a subject comprising:
- (a) a first composition comprising a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the glycoprotein amino acid 194 is serine and the glycoprotein amino acid 333 is glutamic acid, wherein said recombinant rabies virus does not express a foreign protein antigen;
- and
- (b) a Coronavirus antigen, or a nucleic acid molecule encoding a Coronavirus antigen, wherein the Coronavirus antigen is not expressed by the rabies virus.
A method of immunizing a subject against rabies virus and against a Coronavirus antigen comprising the steps of:
- (a) administering a first composition comprising a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the glycoprotein amino acid 194 is serine and the glycoprotein amino acid 333 is glutamic acid, wherein said recombinant rabies virus does not express a foreign protein antigen;
- and
- (b) administering a second composition comprising a Coronavirus antigen, or a nucleic acid molecule encoding a Coronavirus antigen, wherein the Coronavirus antigen is not expressed by the rabies virus.
A method of immunizing a subject against a Coronavirus antigen comprising the steps of:
- (a) administering a first composition comprising a nonpathogenic recombinant rabies virus comprising at least three copies of a mutated G gene, wherein said mutated G gene encodes a rabies virus glycoprotein wherein the glycoprotein amino acid 194 is serine and the glycoprotein amino acid 333 is glutamic acid, wherein said recombinant rabies virus does not express a foreign protein antigen;
- and
- (b) administering a second composition comprising a Coronavirus antigen, or a nucleic acid molecule encoding a Coronavirus antigen, wherein the Coronavirus antigen is not expressed by the rabies virus.
Dependencies are inferred from the claim text.